Bookbuilding IPO | ₹1,857 Cr | Listed at BSE, NSE | Tue, Jul 30, 2024 - Thu, Aug 1, 2024
Akums Drugs IPO is a book build issue of ₹1,856.74 crores. The issue is a combination of fresh issue of 1.00 crore shares aggregating to ₹680.99 crores and offer for sale of 1.73 crore shares aggregating to ₹1,175.75 crores.
Akums Drugs IPO bidding started from Jul 30, 2024 and ended on Aug 1, 2024. The allotment for Akums Drugs IPO was finalized on Aug 2, 2024. The shares got listed on BSE, NSE on Aug 6, 2024.
Akums Drugs IPO price band is set at ₹679 per share. The lot size for an application is 22. The minimum amount of investment required by an retail is ₹14,938 (22 shares) (based on upper price). The lot size investment for sNII is 14 lots (308 shares), amounting to ₹2,09,132, and for bNII, it is 67 lots (1,474 shares), amounting to ₹10,00,846.
The issue includes a reservation of up to 2,43,902 shares for employees offered at a discount of ₹64.00 to the issue price.
ICICI Securities Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Akums Drugs IPO RHP for detailed Information.
IPO Open
Tue, Jul 30, 2024
IPO Close
Thu, Aug 1, 2024
Issue Price
₹679 per share
Market Cap (Pre-IPO)
To be declared
| IPO Date | 30 Jul to 1 Aug, 2024 |
| Listed on | Tue, Aug 6, 2024 |
| Face Value | ₹2 per share |
| Price Band | ₹646 to ₹679 |
| Issue Price | ₹679 per share |
| Lot Size | 22 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹64.00 |
| Total Issue Size | 2,73,68,143 shares (agg. up to ₹1,857 Cr) |
| Fresh Issue | 1,00,37,708 shares (agg. up to ₹681 Cr) |
| Offer for Sale | 1,73,30,435 shares of ₹2 (agg. up to ₹1,176 Cr) |
| Share Holding Pre Issue | 14,73,56,280 shares |
| Share Holding Post Issue | 15,73,71,007 shares |
| BSE Script Code / NSE Symbol | 544222 / AKUMS |
| ISIN | INE09XN01023 |
Akums Drugs IPO offers total 2,73,68,151 shares. Out of which 2,03,43,188 (74.33%) allocated to QIB, 81,37,276 (29.73%) allocated to QIB (Ex- Anchor), 40,68,637 (14.87%) allocated to NII 27,12,424 (9.91%) allocated to RII and 1,22,05,912 (44.60%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 2,03,43,188 (74.33%) | NA |
| − Anchor Investor Shares Offered | 1,22,05,912 (44.60%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 81,37,276 (29.73%) | NA |
| NII (HNI) Shares Offered | 40,68,637 (14.87%) | NA |
| − bNII > ₹10L | 27,12,425 (9.91%) | 8,806 |
| − sNII < ₹10L | 13,56,212 (4.96%) | 4,403 |
| Retail Shares Offered | 27,12,424 (9.91%) | 1,23,292 |
| Employee Shares Offered | 2,43,902 (0.89%) | NA |
| Total Shares Offered | 2,73,68,151 (100.00%) |
Investors can bid for a minimum of 22 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 22 | ₹14,938 |
| Retail (Max) | 13 | 286 | ₹1,94,194 |
| S-HNI (Min) | 14 | 308 | ₹2,09,132 |
| S-HNI (Max) | 66 | 1,452 | ₹9,85,908 |
| B-HNI (Min) | 67 | 1,474 | ₹10,00,846 |
Akums Drugs IPO raises ₹828.78 crore from anchor investors. Akums Drugs IPO Anchor bid date is July 29, 2024.
📝 Anchor Investors Letter (PDF)
| Bid Date | Mon, Jul 29, 2024 |
| Shares Offered | 1,22,05,912 |
| Anchor Portion (₹ Cr.) | 828.78 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sun, Sep 1, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | Thu, Oct 31, 2024 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.
The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).
The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| NET Worth | 709.50 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/prepayment of all or certain borrowings of our Company | 159.91 |
| 2 | Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited | 227.09 |
| 3 | Funding incremental working capital requirements of our Company | 55.00 |
| 4 | Pursuing inorganic growth initiatives through acquisitions | 27.87 |
| 5 | General corporate purposes | 167.50 |
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 0.11% |
| ROCE | 3.37% |
| Debt/Equity | 0.69 |
| RoNW | -0.57 |
| PAT Margin | 0.02% |
| Price to Book Value | 13.69 |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 82.48% | 75.29% |
The Akums Drugs and Pharmaceuticals IPO is subscribed 63.44 times on August 1, 2024 6:19:08 PM (Day 3). The public issue subscribed 20.8 times in the retail category, 90.09 times in the QIB category, and 42.1 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 90.09 | 81,37,276 | 73,31,17,770 |
| NII | 42.1 | 40,68,637 | 17,13,07,510 |
| bNII (bids above ₹10L) | 47.43 | 27,12,425 | 12,86,49,664 |
| sNII (bids below ₹10L) | 31.45 | 13,56,212 | 4,26,57,846 |
| Retail | 20.8 | 27,12,424 | 5,64,23,114 |
| Employee | 4.14 | 2,43,902 | 10,08,810 |
| Total | 63.44 | 1,51,62,239 | 96,18,57,204 |
Total Application : 23,44,029
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission) | 55.88 |
| 2 | Brokerage, selling commission, bidding charges, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs ( | 8.32 |
| 3 | Other expenses (i) Listing fees, SEBI filing fees, BSE & NSE processing fees, book building software fees, (ii) Other regulatory expenses, (iii) Printing and stationery expenses (iv) Fees payable to the legal counsel (v) Fees payable to other advisors to the Offer (vi) Fees payable to the Registrar to the Offer (vii) Miscellaneous | 44.40 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹679.00 | ₹679.00 |
| Open | ₹725.00 | ₹725.00 |
| Low | ₹724.50 | ₹725.00 |
| High | ₹797.45 | ₹797.50 |
| Last Trade | ₹796.35 | ₹796.25 |
Akums Drugs IPO is a main-board IPO of 2,73,68,143 equity shares of the face value of ₹2 aggregating up to ₹1,857 Crores. The issue is priced at ₹679 per share. The minimum order quantity is 22.
The IPO opens on Tue, Jul 30, 2024, and closes on Thu, Aug 1, 2024.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Akums Drugs IPO using UPI as a payment gateway. Zerodha customers can apply in Akums Drugs IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Akums Drugs IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Akums Drugs IPO opens on Tue, Jul 30, 2024 and closes on Thu, Aug 1, 2024.
Akums Drugs IPO lot size is 22, and the minimum amount required for application is ₹14,938.
You can apply in Akums Drugs IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Akums Drugs IPO will be done on Friday, August 2, 2024, and the allotted shares will be credited to your demat account by Mon, Aug 5, 2024. Check the Akums Drugs IPO allotment status.
The Akums Drugs IPO listing date is on Tue, Aug 6, 2024.
